MS and Demyelinating Disorders

Each of the 2 identical twin phase 3 trials, titled ENSURE-1 and ENSURE-2, are expected to enroll approximately 1050 adult patients with active relapsing multiple sclerosis.

Reduced cord cross-sectional area and a higher number of cervical cord lesions were the only significant predictors of an EDSS score equal to 6.0.

The basis for the approval was data from the phase 3 SAkuraSky and SAkuraStar studies, which combined included more than 170 patients who were treated with either satralizumab or placebo.

NeuroMetrix will be evaluating the effectiveness of the transcutaneous electrical nerve stimulation platform in pain relief for patients with neuromyelitis optica spectrum disorder.

Although existing research has shown structural differences between multiple sclerosis and neuromyelitis optica spectrum disorder in following optic neuritis, the new report also covers non–optic neuritis eyes.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 2, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Scott D. Newsome, DO, and David Li, MD, FRCPC.

Longer exposure to disease-modifying therapy over the follow-up period reduced the risk of disability worsening among pregnant people with multiple sclerosis.

Experts in multiple sclerosis (MS) provide an overview of treatment strategies and selection in relapsing MS.

Fred D. Lublin, MD discusses the diagnosis of multiple sclerosis and the 2017 revisions of the McDonald criteria.  

Robert Zivadinov, MD, PhD, director, Buffalo Neuroimaging Analysis Center, spoke to the findings of a post-hoc analysis of atrophied T2-lesion volume as a biomarker in patients with progressive MS.

Here's what is coming soon to NeurologyLive.

We kindly ask you to share 5 minutes of your time with us in order to help us better understand how you use social media and how we can better serve you across different platforms.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 25, 2021.

A significantly higher percentage of patients treated with ublituximab compared to those on teriflunomide achieved no evidence of disease activity status.

Alise Carlson, MD, resident of Cleveland Clinic, details the factors and long-term effects misdiagnosing a patient with multiple sclerosis can have on their quality of life.

At baseline, a negative correlation was noted between average cognition and VAN importance in both groups, indicating that lower VAN importance is related to a higher average cognition.

Advice to community physicians and neurologists who play a role in caring for patients with multiple sclerosis in community practices on optimizing therapy with high-efficacy and newer treatment options.

Here's what is coming soon to NeurologyLive.

The head of global research and executive vice president of Atara Biotherapeutics discussed the upcoming study evaluating ATA188.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 18, 2021.

Join Ahmed Obeidat, MD, PhD; Anne Cross, MD; and Gloria von Geldern, MD, for the third program in this series, where they offer insight from neurology specialists on applying lessons learned from the COVID-19 pandemic into clinical practice when managing patients with multiple sclerosis.

The nurse practitioner at the Woodruff School of Nursing at Emory University detailed why a cultural shift is needed to incorporate APCs into the neurology space and thus improve multidisciplinary care.

All agree that having a simple, standardized serum biomarker to measure disease activity would offer the greatest utility in treating a medical condition such as MS, which now has a variety of graded therapies available.